Clinical Trial Update: Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial assessing ambroxol therapy for Gaucher disease type 1 patients with suboptimal response to enzyme replacement therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type

Drugs mentioned

• Ambroxol (Ambroxol)

Snippet

Sponsor: Shaare Zedek Medical Center | Conditions: Gaucher Disease, Type 1 | Phase 2 | Status: COMPLETED